AI Market Mood: Stock Dashboard
SMMT
Fundamental
Company: Summit Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -1.24
Insider Own: 86.17%
Shs Outstand: 744.44M
Perf Week: -0.20%
Market Cap: 11.14B
Forward P/E: -
EPS next Y: -0.90
Insider Trans: 0.20%
Shs Float: 102.98M
Perf Month: -15.24%
Enterprise Value: 10.90B
PEG: -
EPS next Q: -0.09
Inst Own: 14.07%
Short Float: 35.90%
Perf Quarter: -20.55%
Income: -921.61M
P/S: -
EPS this Y: -233.75%
Inst Trans: 2.77%
Short Ratio: 13.83
Perf Half Y: -43.44%
Sales: 0.00M
P/B: 57.93
EPS next Y Percentage: 13.33%
ROA: -241.08%
Short Interest: 36.96M
Perf YTD: -14.47%
Book/sh: 0.26
P/C: 46.62
EPS next 5Y: -
ROE: -292.49%
52W High: 36.91 -59.47%
Perf Year: -31.44%
Cash/sh: 0.32
P/FCF: -
EPS past 3/5Y: 31.56% -10.52%
ROIC: -472.69%
52W Low: 13.83 8.17%
Perf 3Y: 622.71%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 5.08%
Volatility M: 5.21%
Perf 5Y: 94.29%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -348.63%
Oper. Margin: -
ATR (14): 0.86
Perf 10Y: 103.53%
Dividend Ex-Date: -
Quick Ratio: 3.80
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 43.20
Recom: 1.59
Dividend Gr. 3/5Y: - -
Current Ratio: 3.80
EPS Q/Q: -302.84%
SMA20: -3.10%
Beta: -1.41
Target Price: 32.43
Payout: -
Debt/Eq: 0.03
Sales Q/Q: -
SMA50: -11.51%
Rel Volume: 0.81
Prev Close: 14.63
Employees: 159
LT Debt/Eq: 0.01
Earnings: Oct 20 BMO
SMA200: -28.68%
Avg Volume: 2.67M
Price: 14.96
IPO: Mar 05, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: -82.25% -
Trades:
Volume: 2,165,394
Change: 2.26%
Technical:
Latest News:
Citigroup Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation very bullish
SMMT
Summary: Citigroup initiated coverage of Summit Therapeutics with a Buy recommendation, projecting a 53.67% upside potential. Various funds and institutions are increasing their positions, with a bullish sentiment indicated by the put/call ratio of 0.35.
Full article2024-05-08T17:42:16Z